Cover Image
市場調查報告書

PharmaPoint:思覺失調症 - 全球醫藥品的預測與市場分析

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

出版商 GlobalData 商品編碼 300563
出版日期 內容資訊 英文 433 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:思覺失調症 - 全球醫藥品的預測與市場分析 PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025
出版日期: 2016年11月01日 內容資訊: 英文 433 Pages
簡介

本報告提供主要7個國家 (美國,歐洲主要5個國家 (法國·德國·義大利·西班牙·英國),日本) 的思覺失調症治療藥市場現況與未來展望相關分析,提供您疾病概要和今後的流行病學預測,主要國家的治療體制,主要企業簡介與代表性產品,市場未滿足需求與未來性的機會,現在臨床實驗中的開發中產品資訊,今後的市場規模及影響要素等調查。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理
  • 分類
  • 症狀
  • 流逝
  • 預後

第4章 流行病學

  • 疾病的背景
  • 風險要素和共生病症
  • 全球各國的趨勢
    • 美國
    • (5EU)歐洲主要5個國家
    • 日本
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 思覺失調症的流行病學的預測 (今後11年份)
    • (連續12個月) 接受診斷的患病人數
    • 各年齡的患病人數
    • 男女的患病人數
    • 年齡已調整的患病人數
  • 議論
    • 流行病學的預測相關考察
    • 分析的限制
    • 分析的優勢

第5章 疾病的管理

  • 診斷概要
    • 臨床評估
  • 治療概要
    • 治療的開始
    • 維持療法
    • 突破性事件的治療
    • 長效型的注射劑
    • 對治療藥的抗性
    • 急性興奮
    • 補助性的心理治療
  • 治療指南與代表性的處方藥
  • 美國
  • 歐洲主要5個國家
  • 日本

第6章 競爭企業的評估

  • 概要
  • 產品簡介:非典型抗精神病藥物
    • Abilify (Aripiprazole)
    • Aristada (Aripiprazole·raurokishiru)
    • Clozapine (widely genericized)
    • Fanapt (Iloperidone)
    • Geodon (jipurashidon)
    • Invega (pariperidon)
    • Latuda (Lurasidone)
    • Lonasen (blonanserin)
    • Rexulti (brexpiprazole)
    • Risperdal (risperidone)
    • Saphris (asenapine)
    • Seroquel (Quetiapine)
    • Vraylar (cariprazine)
    • Zyprexa (olanzapine)
  • 產品簡介:典型抗精神病藥物
    • 典型抗精神病藥物
    • Adasuve (Staccato loxapine)
  • 其他治療類

第7章 未滿足需求與市場機會

  • 概要
  • 認知增強藥的開發
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 陰性症狀治療藥的開發
  • 藥物抗性患者用的改良型治療選擇
  • 強化安全型藥物的開發
  • 開發可促進患者遵醫囑服藥的醫藥品

第8章 開發平台評估

  • 概要
  • 臨床實驗階段的有潛力醫藥品
  • 其他臨床實驗中的醫藥品

第9章 現在·未來市場參與企業

  • 概要
  • 企業策略的趨勢
  • 企業簡介

第10章 市場未來展望

  • 全球市場
    • 未來預測
    • 市場促進·阻礙因素
  • 美國
  • 歐洲主要5個國家
  • 日本

第11章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC136PIDR

Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized by several symptom domains including positive symptoms (such as hallucinations or delusions and disorganized speech), negative symptoms (such as a flat affect and poverty of speech), and cognitive deficits (including attention, memory, and executive functions). A multitude of antipsychotic products are currently available for the pharmacological management of schizophrenia, many of which are already available as inexpensive generics. Further patent and exclusivity losses in key franchises throughout the forecast period will act as a barrier to growth in the 7MM, making the schizophrenia market more competitive and crowded. Growth in the schizophrenia market is expected to be driven by the potential introduction of six promising late-stage pipeline products into the market during the forecast period, all of which are directed towards significant unmet needs.

Highlights

Key Questions Answered

  • The schizophrenia market is widely genericized and many of the unexpired patents are due to expire during the forecast period. In light of this, what are the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers throughout the forecast period?
  • There are five substantial unmet needs that exist in the schizophrenia market. Will pipeline drugs fulfil any of the unmet needs for schizophrenia? Which unmet needs will continue to provide opportunity for drug developers during the forecast period?
  • Out of the nine late-stage pipeline products, six of these are expected to launch during the forecast period to 2025. What impact will these drugs have on the market? How will they affect the treatment algorithm for schizophrenia?

Key Findings

  • The main driver of growth in the schizophrenia market will be the uptake of novel pipeline products, such as Minerva Neuroscience's MIN-101, Intra-Cellular Therapies' ITI-007, and Alkermes' ALKS-3831. The pipeline products are forecast to account for 36.2% of the schizophrenia market by 2025 in the 7MM.
  • Several pharma companies have focused on developing long acting injectable (LAI) formulations of their oral brands to tailor treatment plans according to patient's individual needs and improve patient compliance, which is a notable unmet need. Despite the growing popularity of LAIs, this segment is becoming increasingly competitive with three further late-stage pipeline products expected to be launched during the forecast period.
  • There are currently no products approved for the treatment of negative symptoms or cognitive impairments associated with schizophrenia, and only one drug approved for treatment-resistant patients. These constitute the major unmet needs in the schizophrenia market.
  • The biggest barrier for growth in the schizophrenia market will be fierce competition from generic products. This limits market opportunities for new and existing players, as uptake of novel pipeline products would be hindered by their premium price point.

Scope

  • Overview of schizophrenia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized schizophrenia market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the schizophrenia therapeutics market.
  • Pipeline analysis: focus on nine late-stage pipeline schizophrenia drugs, discussing emerging trends as well as an overview of earlier phase drugs.
  • Analysis of the current and future market competition in the global schizophrenia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global schizophrenia therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global schizophrenia therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global schizophrenia therapeutics market from 2015-2025.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms
  • 3.4. Course
  • 3.5. Prognosis

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Forecast Assumptions and Methods
    • 4.4.3. Sources Not Used
  • 4.5. Epidemiological Forecast for Schizophrenia (2015-2025)
    • 4.5.1. 12-Month Diagnosed Prevalent Cases of Schizophrenia
    • 4.5.2. Age-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia
    • 4.5.3. Sex-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia
    • 4.5.4. Age-Standardized 12-Month Diagnosed Prevalence of Schizophrenia
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis Overview
    • 5.1.1. Clinical Evaluation
  • 5.2. Treatment Overview
    • 5.2.1. Treatment Initiation
    • 5.2.2. Maintenance Treatment
    • 5.2.3. Treatment of Breakthrough Episodes
    • 5.2.4. Long-Acting Injectables
    • 5.2.5. Treatment-Resistance
    • 5.2.6. Acute Agitation
    • 5.2.7. Adjunctive Psychotherapy
  • 5.3. Treatment Guidelines and Leading Prescribed Drugs
  • 5.4. US
  • 5.5. 5EU
  • 5.6. Japan

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Atypical Antipsychotics
    • 6.2.1. Abilify (aripiprazole)
    • 6.2.2. Aristada (aripiprazole lauroxil)
    • 6.2.3. Clozapine (widely genericized)
    • 6.2.4. Fanapt (iloperidone)
    • 6.2.5. Geodon (ziprasidone)
    • 6.2.6. Invega (paliperidone)
    • 6.2.7. Latuda (lurasidone)
    • 6.2.8. Lonasen (blonanserin)
    • 6.2.9. Rexulti (brexpiprazole)
    • 6.2.10. Risperdal (risperidone)
    • 6.2.11. Saphris (asenapine)
    • 6.2.12. Seroquel (quetiapine)
    • 6.2.13. Vraylar (cariprazine)
    • 6.2.14. Zyprexa (olanzapine)
  • 6.3. Product Profiles - Typical Antipsychotics
    • 6.3.1. Typical Antipsychotics
    • 6.3.2. Adasuve (Staccato loxapine)
  • 6.4. Other Therapeutic Classes

7. Unmet Needs and Opportunities

  • 7.1. Overview
  • 7.2. Development of Cognitive-Enhancing Drugs
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Development of Drugs to Treat Negative Symptoms
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Improved Treatment Options for Treatment-Resistant Patients
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Development of Drugs with Enhanced Safety Profiles
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Development of Drugs to Increase Compliance
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
    • 8.1.1. Clinical Trials by Class of Therapy
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. ALKS-3831
    • 8.2.2. ITI-007
    • 8.2.3. Lu AF35700
    • 8.2.4. MIN-101
    • 8.2.5. Risperidone implant
    • 8.2.6. Risperidone ISM
    • 8.2.7. RBP-7000
    • 8.2.8. AVN-211
    • 8.2.9. NaBen
  • 8.3. Other Drugs in Development

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Alkermes
    • 9.3.2. Dainippon Sumitomo
    • 9.3.3. Eli Lilly
    • 9.3.4. Intra-Cellular Therapies
    • 9.3.5. Janssen
    • 9.3.6. Lundbeck
    • 9.3.7. Minerva Neurosciences
    • 9.3.8. Otsuka

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed Schizophrenia Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Launch and Patent Expiry Dates
    • 11.4.4. General Pricing Assumptions
    • 11.4.5. Individual Drug Assumptions
    • 11.4.6. Generic Erosion
    • 11.4.7. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for this Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Therapy Area Director
    • 11.7.3. Epidemiologist
    • 11.7.4. Managing Epidemiologist
    • 11.7.5. Global Director of Therapy Analysis and Epidemiology
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: DSM-V Schizophrenia Specifiers
  • Table 2: Classification of Schizophrenia According to DSM-IV and ICD-10
  • Table 3: Other Schizophrenia Spectrum Disorders, 2015
  • Table 4: Symptoms of Schizophrenia
  • Table 5: Risk Factors and Comorbidities for Schizophrenia
  • Table 6: 7MM, Sources of 12-Month Diagnosed Prevalence Data
  • Table 7: 7MM, 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages ≥13 Years, Both Sexes, N, Select Years, 2015-2025
  • Table 8: 7MM, Age-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages ≥13 Years, Both Sexes, N (Row %), 2015
  • Table 9: 7MM, Sex-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages ≥13 Years, N (Row %), 2015
  • Table 10: Treatment Guidelines for Schizophrenia
  • Table 11: Most Prescribed Drugs for Schizophrenia in the 7MM, 2015
  • Table 12: Country Profile - US
  • Table 13: Country Profile - 5EU
  • Table 14: Country Profile - Japan
  • Table 15: Leading Treatments for Schizophrenia, 2015
  • Table 16: Product Profile - Abilify
  • Table 17: Efficacy Results for Abilify in Schizophrenia Trials
  • Table 18: Efficacy Results for Abilify in Schizophrenia Trials
  • Table 19: AEs at ≥2% Incidence in Schizophrenia and Bipolar I Disorder Trials of Abilify
  • Table 20: AEs at ≥2% Incidence in a Schizophrenia Trial of Abilify Maintena
  • Table 21: Abilify SWOT Analysis, 2016
  • Table 22: Product Profile - Aristada
  • Table 23: Efficacy Results for Aristada in Schizophrenia Trial
  • Table 24: AEs at ≥2% Incidence in a Schizophrenia Trial of Aristada
  • Table 25: Aristada SWOT Analysis, 2016
  • Table 26: Product Profile - Clozapine
  • Table 27: Efficacy Results for Clozapine in Treatment-Resistant Schizophrenia Patients
  • Table 28: AEs at ≥5% Incidence in a Short-Term Trial of Clozapine
  • Table 29: AEs at ≥2% Incidence in All Clinical Trials of Clozapine (Excluding InterSePT)
  • Table 30: AEs at ≥10% Incidence During the InterSePT Trial of Clozapine
  • Table 31: Clozapine SWOT Analysis, 2016
  • Table 32: Product Profile - Fanapt
  • Table 33: AEs at ≥2% Incidence in Short-Term Trials of Fanapt
  • Table 34: Fanapt SWOT Analysis, 2016
  • Table 35: Product Profile - Geodon
  • Table 36: AEs at ≥2% Incidence in Schizophrenia Trials of Geodon
  • Table 37: Geodon SWOT Analysis, 2016
  • Table 38: Product Profile - Invega
  • Table 39: Efficacy of Invega Sustenna in Adult Schizophrenia Short-Term Trials
  • Table 40: AEs at ≥2% Incidence in Adult Schizophrenia Trials of Invega
  • Table 41: AEs at ≥2% Incidence in an Adolescent Schizophrenia Trial of Invega
  • Table 42: AEs at ≥2% Incidence in Schizophrenia Trials of Invega Sustenna
  • Table 43: AEs at ≥2% Incidence in a Long-Term Maintenance Trial of Invega Trinza in Schizophrenic Patients
  • Table 44: Invega SWOT Analysis, 2016
  • Table 45: Product Profile - Latuda
  • Table 46: Efficacy Results for Latuda in Schizophrenia Trials
  • Table 47: AEs at ≥2% Incidence in Schizophrenia Trials of Latuda
  • Table 48: Latuda SWOT Analysis, 2016
  • Table 49: Product Profile - Lonasen
  • Table 50: Efficacy Results for Lonasen in Haloperidol-Controlled Clinical Trial
  • Table 51: Efficacy Results for Lonasen in Risperidone-Controlled Clinical Trial
  • Table 52: AEs at ≥5% Incidence in a Short-Term Trial of Lonasen
  • Table 53: Lonasen SWOT Analysis, 2016
  • Table 54: Product Profile - Rexulti
  • Table 55: Efficacy Results for Rexulti in Short-Term Schizophrenia Trials
  • Table 56: AEs at ≥2% Incidence in Schizophrenia Trials of Rexulti
  • Table 57: Rexulti SWOT Analysis, 2016
  • Table 58: Product Profile - Risperdal
  • Table 59: Efficacy Results for Risperdal Consta in a 12-Week Schizophrenia Study
  • Table 60: AEs at ≥2% Incidence in Adult Schizophrenia Trials of Risperdal
  • Table 61: AEs at ≥5% Incidence in a Pediatric Schizophrenia Trial of Risperdal
  • Table 62: AEs at ≥5% Incidence in an Adult Schizophrenia Trial of Risperdal Consta
  • Table 63: Risperdal SWOT Analysis, 2016
  • Table 64: Product Profile - Saphris
  • Table 65: Efficacy Results for Saphris in Short-Term Schizophrenia Trials
  • Table 66: AEs at ≥2% Incidence in Schizophrenia Trials of Saphris
  • Table 67: Saphris SWOT Analysis, 2016
  • Table 68: Product Profile - Seroquel
  • Table 69: Efficacy Results for Seroquel in a Six-Week Schizophrenia Study
  • Table 70: Efficacy Results for Seroquel in Short-Term Schizophrenia Studies
  • Table 71: Efficacy Results for Seroquel XR in Schizophrenia Trials
  • Table 72: AEs at ≥2% Incidence in Adult Schizophrenia and Bipolar Mania Trials of Seroquel
  • Table 73: AEs at ≥2% Incidence in a Short-Term Trial of Seroquel in Schizophrenic Adolescents
  • Table 74: AEs at ≥2% Incidence in Six-Week Trials of Seroquel XR in Schizophrenic Adults
  • Table 75: Seroquel SWOT Analysis, 2016
  • Table 76: Product Profile - Vraylar
  • Table 77: Efficacy Results for Vraylar in a Six-Week Schizophrenia Study
  • Table 78: Efficacy Results for Vraylar in Short-Term Schizophrenia Studies
  • Table 79: AEs at ≥2% Incidence in Short-Term Schizophrenia Trials of Vraylar
  • Table 80: Vraylar SWOT Analysis, 2016
  • Table 81: Product Profile - Zyprexa
  • Table 82: AEs at ≥5% Incidence in Adult Schizophrenia Trials of Zyprexa
  • Table 83: AEs at ≥2% Incidence in Short-Term Trials of Zyprexa
  • Table 84: AEs at ≥1% Incidence in Adult Schizophrenia Trials of Zyprexa IntraMusular
  • Table 85: AEs at ≥5% Incidence in Adolescent Schizophrenia Trials of Zyprexa
  • Table 86: AEs Reported at ≥2% Incidence in a Schizophrenia Trial of Zyprexa Relprevv
  • Table 87: Zyprexa SWOT Analysis, 2016
  • Table 88: Typical antipsychotics SWOT Analysis, 2016
  • Table 89: Product Profile - Adasuve
  • Table 90: Efficacy Results for Adasuve in Agitation Trial of Schizophrenia Patients
  • Table 91: Decrease in FEV1 in Pulmonary Safety Trials of Adasuve
  • Table 92: Adasuve SWOT Analysis, 2016
  • Table 93: Summary of Minor Therapeutic Classes, 2015
  • Table 94: Unmet Need and Opportunity in Schizophrenia
  • Table 95: Product Profile - ALKS-3831
  • Table 96: ALKS-3831 SWOT Analysis, 2016
  • Table 97: Product Profile - ITI-007
  • Table 98: Efficacy Results for ITI-007 in a Phase II Schizophrenia Trial
  • Table 99: Key Safety Data From a Phase II in a Schizophrenia Trial of ITI-007
  • Table 100: ITI-007 SWOT Analysis, 2016
  • Table 101: Product Profile - Lu AF35700
  • Table 102: Lu AF35700 SWOT Analysis, 2016
  • Table 103: Product Profile - MIN-101
  • Table 104: Efficacy Results for MIN-101 in a 12-Week Phase IIb Schizophrenia Study
  • Table 105: Safety Evaluation of MIN-101 Phase IIa Clinical Trial in Schizophrenia
  • Table 106: AEs at ≥5% Incidence in a Phase IIb Schizophrenia Trial of MIN-101
  • Table 107: Safety Evaluation of MIN-101 Phase IIb Clinical Trial in Schizophrenia
  • Table 108: MIN-101 SWOT Analysis, 2016
  • Table 109: Product Profile - Risperidone Implant
  • Table 110: Risperidone Implant SWOT Analysis, 2016
  • Table 111: Product Profile - Risperidone ISM
  • Table 112: Risperidone ISM SWOT Analysis, 2016
  • Table 113: Product Profile - RBP-7000
  • Table 114: Efficacy Results for RBP-7000 in a Phase III Schizophrenia Trial
  • Table 115: AEs reported in a Phase III Schizophrenia Trial of RBP-7000A
  • Table 116: RBP-7000 SWOT Analysis, 2016
  • Table 117: Product Profile - AVN-211
  • Table 118: Attention tests and measures evaluated in a Phase IIa Schizophrenia Trial of AVN-211
  • Table 119: Psychometric Results in a Phase IIa Schizophrenia Trial of AVN-211
  • Table 120: Results of the Attention Measures that Showed Significant Changes in a Phase IIa Schizophrenia Trial of AVN-211
  • Table 121: AVN-211 SWOT Analysis, 2016
  • Table 122: Product Profile - NaBen
  • Table 123: PANSS Clinical Measures During the Phase II Trial of Sodium Benzoate Adjunctive Therapy in Schizophrenia
  • Table 124: Other Clinical Measures During the Phase II Trial of Sodium Benzoate Adjunctive Therapy in Schizophrenia
  • Table 125: Cognitive Measures During the Phase II Trial of Sodium Benzoate Adjunctive Therapy in Schizophrenia
  • Table 126: NaBen SWOT Analysis, 2016
  • Table 127: Drugs in Development for Schizophrenia, 2015
  • Table 128: Key Companies in the Schizophrenia Market in the 7MM, 2015
  • Table 129: Alkermes' Schizophrenia Portfolio Assessment, 2015
  • Table 130: Alkermes SWOT Analysis in Schizophrenia, 2015-2025
  • Table 131: Dainippon Sumitomo's Schizophrenia Portfolio Assessment, 2015
  • Table 132: Dainippon Sumitomo SWOT Analysis in Schizophrenia, 2015-2025
  • Table 133: Eli Lilly's Schizophrenia Portfolio Assessment, 2015
  • Table 134: Eli Lilly SWOT Analysis in Schizophrenia, 2015-2025
  • Table 135: Intra-Cellular Therapies' Schizophrenia Portfolio Assessment, 2015
  • Table 136: Intra-Cellular Therapies SWOT Analysis in Schizophrenia, 2015-2025
  • Table 137: Janssen's Schizophrenia Portfolio Assessment, 2015
  • Table 138: Janssen SWOT Analysis in Schizophrenia, 2015-2025
  • Table 139: Lundbeck's Schizophrenia Portfolio Assessment, 2015
  • Table 140: Lundbeck SWOT Analysis in Schizophrenia, 2015-2025
  • Table 141: Minerva Neurosciences' Schizophrenia Portfolio Assessment, 2015
  • Table 142: Minerva Neurosciences SWOT Analysis in Schizophrenia, 2015-2025
  • Table 143: Otsuka's Schizophrenia Portfolio Assessment, 2015
  • Table 144: Otsuka SWOT Analysis in Schizophrenia, 2015-2025
  • Table 145: Schizophrenia Market - Drivers and Barriers, 2015-2025
  • Table 146: Key Events Impacting Sales for Schizophrenia in the US, 2015-2025
  • Table 147: Schizophrenia Market in the US - Drivers and Barriers, 2015-2025
  • Table 148: Key Events Impacting Sales for Schizophrenia in the 5EU, 2015-2025
  • Table 149: Schizophrenia Market in the 5EU - Drivers and Barriers, 2015-2025
  • Table 150: Key Events Impacting Sales for Schizophrenia in Japan, 2015-2025
  • Table 151: Schizophrenia Market in Japan - Drivers and Barriers, 2015-2025
  • Table 152: Key Launch Dates
  • Table 153: Key Patent/Exclusivity Expiries
  • Table 154: High-Prescribing Psychiatrists (Non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Longitudinal Course of Schizophrenia
  • Figure 2: 7MM, 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages ≥13 Years, Both Sexes, N, Select Years, 2015-2025
  • Figure 3: 7MM, Age-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages ≥13 Years, Both Sexes, N, 2015
  • Figure 4: 7MM, Sex-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages ≥13 Years, N, 2015
  • Figure 5: 7MM, Age-Standardized 12-Month Diagnosed Prevalence of Schizophrenia (Cases per 100,000 Population), Ages ≥13 Years, Both Sexes, 2015
  • Figure 6: Schizophrenia Therapeutics - Class of Therapy, 2016
  • Figure 7: Schizophrenia - Promising Late-Stage Phase IIb-III Pipeline Drugs, 2016
  • Figure 8: Competitive Assessment of Promising Late-Stage Pipeline Agents in Schizophrenia, 2015-2025
  • Figure 9: Clinical and Commercial Positioning of ALKS-3831
  • Figure 10: Clinical and Commercial Positioning of ITI-007
  • Figure 11: Clinical and Commercial Positioning of Lu AF35700
  • Figure 12: Clinical and Commercial Positioning of MIN-101
  • Figure 13: Clinical and Commercial Positioning of the Risperidone Implant
  • Figure 14: Clinical and Commercial Positioning of Risperidone ISM
  • Figure 15: Clinical and Commercial Positioning of RBP-7000
  • Figure 16: Clinical and Commercial Positioning of AVN-211
  • Figure 17: Clinical and Commercial Positioning of NaBen
  • Figure 18: Global Sales of Products for Schizophrenia by Company, 2015-2025
  • Figure 19: Company Portfolio Gap Analysis in Schizophrenia, 2015-2025
  • Figure 20: Global Sales for Schizophrenia by Region, 2015-2025
  • Figure 21: Global Sales for Schizophrenia by Drug Class, 2015-2025
  • Figure 22: Sales for Schizophrenia in the US by Drug Class, 2015-2025
  • Figure 23: Sales for Schizophrenia in the 5EU by Drug Class, 2015-2025
  • Figure 24: Sales for Schizophrenia in Japan by Drug Class, 2015-2025
Back to Top